Molecular Characterization and Clinical Impact of TMPRSS2-ERG Rearrangement on Prostate Cancer: Comparison between FISH and RT-PCR

Table 5

Log-rank and Cox regression tests for BPFS and clinical PFS in the 294 cases analyzed.

Parameters	𝑛	Biochemical progression						Clinical progression
		Events	%BPFS	P-univariate	HR	95% CI	P-multivariate	Events	% Clinical PFS	P-univariate	HR	95% CI	P-multivariate
PSA
≤10 ng/mL	186	37	53.6		1		0.001	20	77.7
10–20 ng/mL	66	26	50.4	<0.001	2.9	1.6–5.3	<0.001	18	52.3	0.015	NS
>20 ng/mL	42	20	28.2		1.6	0.8–3	0.118	12	51.9
Gleason-sp
2–6	118	21	67.7		1		<0.001	11	78.4		1		0.001
7	139	39	46.3	<0.001	4.4	2.2–8.5	<0.001	26	59	<0.001	4.8	2–11.1	<0.001
>7	37	23	0		3.2	1.8–5.7	<0.001	13	48		2.5	1.3–5	0.008
cT
≤cT2b	274	72	51.4	0.001	NS			45	65.7	0.410	NS
≥cT3a	19	11	26.4					5	65.4
pT
≤pT2	161	24	68.3	<0.001	NS			14	77.8	0.001	NS
≥pT3	133	59	35.4					36	56.7
pN
pN0	66	125	50	<0.001	1		0.033	40	67.6	0.004	NS
pN ≥ 1	9	1	0		2.3	1.1–5.1		5	33.8
Perineural inv.
Negative	126	24	56.9	<0.001	1		0.001	13	82.9	0.001	1		0.013
Positive	144	58	44.7		2.4	1.4–4		36	50.8		2.3	1.2–4.5
TMPRSS2-ERG
Negative	132	31	58.7					18	74.3
Translocation	118	39	39.3	0.229				24	60.1	0.380
Deletion	35	10	39.4					6	72.4
Fusion gene status
Negative	127	35	51	0.824				22	68	0.855
Positive	166	47	48.2					26	67.7

SP: specimen, BPFS: biochemical progression free survival, PFS: progression free survival, and NS: not significant.